Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

Palisade Bio, Inc. announced that it has entered into a licensing agreement with Giiant Pharma, Inc. The license provides the company with the exclusive worldwide rights to develop, manufacture, and commercialize Giiant’s proprietary targeted prodrug platform focused on therapies for the multi-billion dollar inflammatory bowel disease market.